Crescent Biopharma and Kelun-Biotech Announce Reciprocal Licensing Pact for PD-1xVEGF and ADC Cancer Therapies

Crescent Biopharma and Kelun-Biotech have entered a strategic partnership to develop and commercialize Crescent's PD-1xVEGF bispecific antibody (CR-001) and Kelun's ITGB6-directed ADC (SKB105) 1 3 4.

Kelun receives exclusive rights to CR-001 in Greater China, while Crescent gains exclusive rights to SKB105 outside Greater China 1 2 4.

The deal includes an upfront payment of $80 million from Crescent to Kelun, with up to $1.25 billion in milestones for SKB105 in Greater China, and $20 million upfront from Kelun to Crescent, with up to $30 million in milestones for CR-001 outside Greater China 1 3 4.

Both CR-001 and SKB105 are expected to enter Phase 1/2 monotherapy trials in Q1 2026, with combination studies planned for later in 2026 and 2027 1 4.

The collaboration aims to accelerate clinical development and combination strategies for solid tumors, leveraging each company's regional strengths and clinical resources 1 2 4.

Sources:

1. https://www.stocktitan.net/news/CBIO/kelun-biotech-and-crescent-biopharma-announce-strategic-partnership-7h7uwdj6e1s9.html

2. https://medcitynews.com/2025/12/crescent-biopharma-bispecific-antibody-drug-conjugate-cancer-kelun-biotech-pd1-vegf-itgb6-adc-cbio/

3. https://www.biospace.com/business/crescent-kelun-biotech-swap-therapies-in-adc-bispecific-deal-worth-up-to-1-25b

4. https://www.globenewswire.com/news-release/2025/12/04/3199605/0/en/Crescent-Biopharma-Announces-Transformational-Partnership-with-Kelun-Biotech-and-185-Million-Private-Placement-Accelerating-and-Expanding-Global-Pipeline-of-Next-Generation-Therape.html

Sources:

Leave a Reply Cancel reply